ICER Releases Draft Evidence Report for Sickle Cell Disease – Pricing Signals for CGT Pricing
Last week, the Institute for Clinical and Economic Review (ICER) published its draft evidence report for sickle cell disease. The report assesses initial cost-effectiveness thresholds for two potential gene therapies against existing standard of care.